FDA Outlines GMPs for Drugmakers Dealing With COVID-19 Infections in Workers

The FDA on Friday released guidance for drugmakers on good manufacturing practices (GMPs) for responding to COVID-19 infection in employees.

Workers in drug manufacturing facilities are deemed to be “essential critical infrastructure” workers during the pandemic, the agency said. Employees who test positive for COVID-19 or have symptoms should not return to work until they have fulfilled the isolation criteria outlined by the Centers for Disease Control and Prevention.

Read the full guidance here: www.fdanews.com/06-19-20-GMPConsiderations.pdf. — Jordan Williams